Considerations in the Development of Physically Stable High Drug Load API- Polymer Amorphous Solid Dispersions in the...

Area of Science:

• Pharmaceutical Sciences
• Materials Science
• Physical Chemistry

Background:

• Amorphous solid dispersions (ASDs) are crucial for improving the solubility and bioavailability of poorly soluble drugs.
• Long-term stability of amorphous active pharmaceutical ingredients (APIs) in ASDs is a significant challenge due to crystallization.
• Understanding the role of polymers in inhibiting API crystallization is key to developing stable drug products.

Purpose of the Study:

• To investigate the impact of polymer concentration on the long-term isothermal crystallization of amorphous APIs in ASDs.
• To identify mechanistic factors governing polymer-mediated inhibition of API crystallization.
• To determine the minimum polymer concentration required for stable high-load amorphous dispersions.

Main Methods:

• Review and analysis of existing literature on API crystallization in ASDs.
• Examination of mechanistic factors: API-polymer interactions, polymer molecular weight, and molecular mobility.
• Focus on the influence of polymer concentration and its spatial distribution within the glassy state.

Main Results:

• Polymers significantly inhibit API crystallization, even at concentrations below 10% w/w.
• Heterogeneous glassy state structure and polymer distribution play critical roles in crystallization inhibition.
• Specific API-polymer interactions and molecular mobility are key factors influencing stability.

Conclusions:

• Low polymer concentrations can effectively stabilize amorphous APIs in high-load dispersions.
• Optimizing polymer characteristics and understanding their distribution are essential for designing stable ASDs.
• This study provides insights into achieving stable, high-dose amorphous formulations with minimal polymer content.